Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (5)

Search Parameters:
Keywords = antiviral therapy
Page = 2

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 3291 KB  
Review
The Noscapine Saga: Unravelling a Valuable Jewel from a Poppy Pod—Past, Present and Future
by Anjali Priyadarshani, Rishit Bhatia and Muniba Shan
Psychoactives 2024, 3(1), 1-21; https://doi.org/10.3390/psychoactives3010001 - 10 Jan 2024
Cited by 2 | Viewed by 7869
Abstract
Noscapine is a naturally occurring alkaloid isolated from Papaver somniferum, commonly known as opium poppy or bread seed poppy. It edges over other opioids as it lacks addictive, sedative or euphoric effects. This review chronicles the saga of endeavours with noscapine, from [...] Read more.
Noscapine is a naturally occurring alkaloid isolated from Papaver somniferum, commonly known as opium poppy or bread seed poppy. It edges over other opioids as it lacks addictive, sedative or euphoric effects. This review chronicles the saga of endeavours with noscapine, from modest efforts in the mid-1950s to its present anticancer potential and futuristic hope in combating COVID-19. We comprehensively searched for publications including noscapine- and noscapinoid-relevant keywords in different electronic databases such as PubMed, Google Scholars, Elsevier, Springer Link and Science Direct up to June 2023. We excluded those in a language other than English. Noscapine has long been used as an antitussive and suppresses coughing by reducing the activity of the cough centre in the brain. A great number of water-soluble noscapine analogues have been found to be impressive microtubule-interfering agents with a superior antiproliferative activity, inhibiting the proliferation of cancer cell lines with more potency than noscapine and bromo-noscapine. With enhanced drug delivery systems, noscapine has exerted significant therapeutic efficacy in animal models of Parkinson’s disease, polycystic ovary syndrome, multiple sclerosis and other disorders. Furthermore, the merit of noscapine in crossing the blood–brain barrier makes it a putative candidate agent against neurodegenerative and psychiatric diseases. Its long safety record, widespread availability and ease of administration make it an ideal candidate for fighting several life-threatening conditions. Recent promising docking studies onnoscapine with main protease (Mpro) of SARS-CoV-2 paves the way for combinatorial drug therapy with anti-viral drugs and is hopeful in fighting and triumphing over any future COVID-19 pandemic. Full article
Show Figures

Figure 1

11 pages, 1174 KB  
Article
Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study
by Saverio Bettuzzi, Luigi Gabba and Simona Cataldo
COVID 2021, 1(1), 2-12; https://doi.org/10.3390/covid1010002 - 31 May 2021
Cited by 26 | Viewed by 10515
Abstract
The lack of therapies for moderate COVID-19 syndrome prompted us to use a standardized polyphenolic green tea extract rich in catechins during the lockdown due to the pandemic in Italy (Autumn 2020). Catechins are powerful antioxidant, anti-inflammatory and antiviral agents that are safe [...] Read more.
The lack of therapies for moderate COVID-19 syndrome prompted us to use a standardized polyphenolic green tea extract rich in catechins during the lockdown due to the pandemic in Italy (Autumn 2020). Catechins are powerful antioxidant, anti-inflammatory and antiviral agents that are safe for human use. While awaiting hospitalization, 10 swab-positive patients, symptomatic for SARS-COV-2, were treated for 15 days at home with two sessions of inhalation plus three capsules per day (total catechins: 840 mg; total EGCG: 595 mg). All patients recovered fully and had no symptoms at a median of 9 days, with a range of 7–15 days. Seven switched to a negative SARS-COV-2 nasopharyngeal swab test at a median of 9 days, with a range of 6–13 days. Among the 3 patients still swab-positive, one had a strong decrease of infection down to a “very low” SARS-COV-2 nucleic acid load at 5 days. All patients exited quarantine at the end of therapy because they were free of symptoms. Inflammation markers α-1 anti-trypsin, C-reactive protein and eosinophils had significantly decreased. The IL-6 and erythrocyte sedimentation rate decreased in 7 out of 10 patients. To the best of our knowledge, this is the first report of the efficacy of green tea catechin against COVID-19 syndrome. These results may open new perspectives in the fight against the disease. Full article
21 pages, 979 KB  
Review
Cyclophilin A: A Key Factor in Virus Replication and Potential Target for Anti-Viral Therapy
by Farman Ullah Dawar, Jiagang Tu, Muhammad Nasir Khan Khattak, Jie Mei and Li Lin
Curr. Issues Mol. Biol. 2017, 21(1), 1-20; https://doi.org/10.21775/cimb.021.001 - 2 Apr 2016
Cited by 58 | Viewed by 1137
Abstract
Cyclophilin A (CypA) is a key member of immunophilins that has peptidyl-prolyl cis/trans isomerase (PPIase) activity. Besides acting as a cellular receptor for immunosuppressive drug cyclosporine A (CsA), CypA is involved in various cellular activities. CypA has an important role in viral infection [...] Read more.
Cyclophilin A (CypA) is a key member of immunophilins that has peptidyl-prolyl cis/trans isomerase (PPIase) activity. Besides acting as a cellular receptor for immunosuppressive drug cyclosporine A (CsA), CypA is involved in various cellular activities. CypA has an important role in viral infection which either facilitates or inhibits their replication. Inhibition of CypA via inhibitors is useful for overcoming several viral infections, indicating that CypA is an attractive target for anti-viral therapy. Collectively, these facts demonstrate the critical roles of CypA in mediating or inhibiting viral infections, suggesting that CypA can be an attractive cellular target for the development of anti-viral therapy. Full article
13 pages, 485 KB  
Review
Classification Framework and Chemical Biology of Tetracycline-Structure-Based Drugs
by Domenico Fuoco
Antibiotics 2012, 1(1), 1-13; https://doi.org/10.3390/antibiotics1010001 - 12 Jun 2012
Cited by 100 | Viewed by 37963
Abstract
By studying the literature about tetracyclines (TCs), it becomes clearly evident that TCs are very dynamic molecules. In some cases, their structure-activity-relationship (SAR) are well known, especially against bacteria, while against other targets, they are virtually unknown. In other diverse fields of research—such [...] Read more.
By studying the literature about tetracyclines (TCs), it becomes clearly evident that TCs are very dynamic molecules. In some cases, their structure-activity-relationship (SAR) are well known, especially against bacteria, while against other targets, they are virtually unknown. In other diverse fields of research—such as neurology, oncology and virology—the utility and activity of the tetracyclines are being discovered and are also emerging as new technological fronts. The first aim of this paper is to classify the compounds already used in therapy and prepare the schematic structure that includes the next generation of TCs. The second aim of this work is to introduce a new framework for the classification of old and new TCs, using a medicinal chemistry approach to the structure of those drugs. A fully documented Structure-Activity-Relationship (SAR) is presented with the analysis data of antibacterial and nonantibacterial (antifungal, antiviral and anticancer) tetracyclines. The lipophilicity and the conformational interchangeability of the functional groups are employed to develop the rules for TC biological activity. Full article
Show Figures

Graphical abstract

7 pages, 628 KB  
Review
RNA Interference: Past, Present and Future
by Tessa N. Campbell and Francis Y.M. Choy
Curr. Issues Mol. Biol. 2005, 7(1), 1-6; https://doi.org/10.21775/cimb.007.001 - 8 Dec 2004
Cited by 1 | Viewed by 1907
Abstract
RNA interference (RNAi) is the sequence-specific gene silencing induced by double-stranded RNA. RNAi is mediated by 21-23 nucleotide small interfering RNAs (siRNAs) which are produced from long double-stranded RNAs by RNAse II-like enzyme Dicer. The resulting siRNAs are incorporated into a RNA-induced silencing [...] Read more.
RNA interference (RNAi) is the sequence-specific gene silencing induced by double-stranded RNA. RNAi is mediated by 21-23 nucleotide small interfering RNAs (siRNAs) which are produced from long double-stranded RNAs by RNAse II-like enzyme Dicer. The resulting siRNAs are incorporated into a RNA-induced silencing complex (RISC) that targets and cleaves mRNA complementary to the siRNAs. Since its inception in 1998, RNAi has been demonstrated in organisms ranging from trypanosomes to nematodes to vertebrates. Potential uses already in progress include the examination of specific gene function in living systems, the development of anti-viral and anti-cancer therapies, and genome-wide screens. In this review, we discuss the landmark discoveries that established the contextual framework leading up to our current understanding of RNAi. We also provide an overview of current developments and future applications. Full article
Back to TopTop